Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19
Copyright © 2020 The Author. Published by Elsevier Ltd.. All rights reserved..
HYPOTHESIS: The delayed lung damage after SARS-CoV-2 infection may be caused by an autoimmune response to ACE2 induced by forced presentation of the ACE2 protein in a complex with CoV Spike in Fc Receptor positive Antigen Presenting Cells in the lung. The likelihood that this hypothesis is valid is low, but it is easily tested.
TESTABLE PREDICTIONS: 1) Autoantibodies and T cells to ACE2 may be found in patients with the lung damage but not in those without 2) There may be an HLA linkage with the delayed lung disease 3) Vaccines based on the spike protein might initiate the process by amplifying Fc mediated uptake of ACE2-Spike complexes into APCs.
PRACTICAL IMPLICATIONS: The development of autoantibodies to ACE2 might predict the development of the inflammatory phase of Covid-19 disease. It might be wise to consider engineering versions of the spike that no longer bind to ACE2 for inclusion in vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Medical hypotheses - 144(2020) vom: 05. Nov., Seite 110043 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Townsend, Alain [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE2 protein, human |
|---|
| Anmerkungen: |
Date Completed 05.01.2021 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mehy.2020.110043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313704899 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313704899 | ||
| 003 | DE-627 | ||
| 005 | 20231225151138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2020.110043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313704899 | ||
| 035 | |a (NLM)32795830 | ||
| 035 | |a (PII)S0306-9877(20)31454-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Townsend, Alain |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2021 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a HYPOTHESIS: The delayed lung damage after SARS-CoV-2 infection may be caused by an autoimmune response to ACE2 induced by forced presentation of the ACE2 protein in a complex with CoV Spike in Fc Receptor positive Antigen Presenting Cells in the lung. The likelihood that this hypothesis is valid is low, but it is easily tested | ||
| 520 | |a TESTABLE PREDICTIONS: 1) Autoantibodies and T cells to ACE2 may be found in patients with the lung damage but not in those without 2) There may be an HLA linkage with the delayed lung disease 3) Vaccines based on the spike protein might initiate the process by amplifying Fc mediated uptake of ACE2-Spike complexes into APCs | ||
| 520 | |a PRACTICAL IMPLICATIONS: The development of autoantibodies to ACE2 might predict the development of the inflammatory phase of Covid-19 disease. It might be wise to consider engineering versions of the spike that no longer bind to ACE2 for inclusion in vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a HLA Antigens |2 NLM | |
| 650 | 7 | |a Receptors, Fc |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Medical hypotheses |d 1983 |g 144(2020) vom: 05. Nov., Seite 110043 |w (DE-627)NLM00007487X |x 1532-2777 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2020 |g day:05 |g month:11 |g pages:110043 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mehy.2020.110043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2020 |b 05 |c 11 |h 110043 | ||